Ranndy joins as Kalium launches Series A funding round
Randy Kellogg has joined the board of Kalium Health as the Cambridge University medtech spinout launches its Series A offering to investors.
The company, which is developing the world’s first blood potassium rapid self-test, is seeking to raise £6m to complete clinical validation activities and enter the US market.
Kalium Health spun out novel blood sensing technology from the University of Cambridge in 2020. The goal is to empower patients and clinicians to save lives and enable new treatments with quick, accurate blood tests suitable for use by anyone, at home or at the point of care.
The company’s initial focus is on the accurate monitoring of blood potassium levels to improve the management of chronic kidney disease, which affects 800 million people worldwide, but the technology has wider applications and could help improve outcomes for a range of diseases. Kalium’s technology has already attracted the attention of US investors who recognise the huge opportunity to create value in chronic kidney disease management, which currently accounts for over 24 per cent of US medicare spend.
Kalium’s cause is significantly boosted by the arrival of US healthcare leader Ranndy Kellogg, president and CEO of Illinois-based Omron Healthcare, who joins the board of Kalium Health.
“Ranndy is recognised globally as a healthcare leader who has generated huge value in remote patient monitoring for chronic diseases through the growth of Omron and also AliveCor, where he also sits on the Board He will draw on his experience of building and scaling medical product companies to support Kalium’s commercial strategy focused on rapid market entry in the fast-growing area of long-term disease management.
Tom Collings, CEO at Kalium Health, said: “While our outlook is global, our decision to prioritise US market entry is based on regulatory considerations and near-term commercial opportunities. Ranndy’s insight and experience will be immensely valuable as our strategy evolves in line with healthcare delivery trends and I am thrilled that he has chosen to work with us on our important mission.”
Randy noted: “Particularly here in the US, as kidney care providers are incentivised to adopt new approaches, this is the right technology at the right time.”
The investment round is set to close in spring 2024.
